{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:02:18Z","timestamp":1791234138239,"version":"4.1.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s13555-022-00848-1","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T01:10:40Z","timestamp":1669165840000},"page":"29-49","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The Role of Systemic and Topical Beta-Blockers in Dermatology: A Systematic Review"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3997-5676","authenticated-orcid":false,"given":"Alya M.","family":"Alhazmi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad A.","family":"Basendwh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah Ayman","family":"Aman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Dajam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turki S.","family":"Aljuhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,22]]},"reference":[{"issue":"24","key":"848_CR1","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1056\/NEJMc0708819","volume":"358","author":"C L\u00e9aut\u00e9-Labr\u00e8ze","year":"2008","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, De La Roque ED, Hubiche T, Boralevi F, Thambo JB, Ta\u00efeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358(24):2649\u201351.","journal-title":"N Engl J Med"},{"issue":"4","key":"848_CR2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/1523-1747.ep12499860","volume":"98","author":"V Steinkraus","year":"1992","unstructured":"Steinkraus V, Steinfath M, K\u00f6rner C, Mensing H. Binding of beta-adrenergic receptors in human skin. J Invest Dermatol. 1992;98(4):475\u201380.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"848_CR3","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1067-1927.2005.130408.x","volume":"13","author":"CE Pullar","year":"2005","unstructured":"Pullar CE, Isseroff RR. \u00df2-adrenergic receptor activation delays dermal fibroblast-mediated contraction of collagen gels via a cAMP-dependent mechanism. Wound Repair Regen. 2005;13(4):405\u201311.","journal-title":"Wound Repair Regen"},{"key":"848_CR4","unstructured":"Autocrine Catecholamine Biosynthesis and the \u03b22-Adrenoceptor Signal Promote Pigmentation in Human Epidermal Melanocytes - ScienceDirect [Internet]. [cited 2022 Jan 14]. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0022202X15309167"},{"key":"848_CR5","doi-asserted-by":"publisher","unstructured":"Innervation and receptor profiles of the human apocrine (epitrichial) sweat gland: routes for intervention in bromhidrosis - Lindsay - 2008 - British Journal of Dermatology - Wiley Online Library [Internet]. [cited 2022 Jan 14]. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/https:\/\/doi.org\/10.1111\/j.1365-2133.2008.08740.x","DOI":"10.1111\/j.1365-2133.2008.08740.x"},{"issue":"372","key":"848_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"29","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;29(372): n71.","journal-title":"BMJ"},{"issue":"2","key":"848_CR7","first-page":"84","volume":"1","author":"GD Puspitasari","year":"2020","unstructured":"Puspitasari GD, Prawitasari S. Combining topical therapy and bisoprolol on refractory venous ulcer. J Dermatol Venereol Aesthetic. 2020;1(2):84\u201394.","journal-title":"J Dermatol Venereol Aesthetic"},{"issue":"2","key":"848_CR8","first-page":"22","volume":"2","author":"F Hajighasemi","year":"2010","unstructured":"Hajighasemi F, Mirshafiey A. Propranolol effect on proliferation and vascular endothelial growth factor secretion in human immunocompetent cells. J Clin Immunol Immunopathol Res. 2010;2(2):22\u20137.","journal-title":"J Clin Immunol Immunopathol Res"},{"issue":"6","key":"848_CR9","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1111\/pcmr.12918","volume":"33","author":"NM Williams","year":"2020","unstructured":"Williams NM, Vincent LT, Rodriguez GA, Nouri K. Antihypertensives and melanoma: an updated review. Pigment Cell Melanoma Res. 2020;33(6):806\u201313.","journal-title":"Pigment Cell Melanoma Res"},{"key":"848_CR10","unstructured":"\u03b2-Adrenergic Receptor Antagonists Accelerate Skin Wound Healing - Journal of Biological Chemistry [Internet]. [cited 2022 Jan 14]. Available from: https:\/\/www.jbc.org\/article\/S0021-9258(18)95250-6\/fulltext"},{"issue":"2","key":"848_CR11","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1001\/jamadermatol.2019.3839","volume":"156","author":"GM Olsen","year":"2020","unstructured":"Olsen GM, Hansen LM, Stefanko NS, Mathes E, Puttgen KB, Tollefson MM, et al. Evaluating the safety of oral propranolol therapy in patients with PHACE syndrome. JAMA Dermatol. 2020;156(2):186\u201390.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"848_CR12","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/pde.13177","volume":"34","author":"CB Bayart","year":"2017","unstructured":"Bayart CB, Tamburro JE, Vidimos AT, Wang L, Golden AB. Atenolol versus propranolol for treatment of infantile hemangiomas during the proliferative phase: a retrospective noninferiority study. Pediatr Dermatol. 2017;34(4):413\u201321.","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"848_CR13","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/pde.13839","volume":"36","author":"ME Gumina","year":"2019","unstructured":"Gumina ME, Yan AC. Atenolol as an alternative to propranolol for the management of sleep disturbances in the treatment of infantile hemangiomas. Pediatr Dermatol. 2019;36(4):556\u20137.","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"848_CR14","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/pde.14484","volume":"38","author":"S Frost","year":"2021","unstructured":"Frost S, Saddi V, Teng A, Mallitt KA, Adams S, Williamson B, et al. Propranolol\u2019s effects on the sleep of infants with hemangiomas: a prospective pilot study. Pediatr Dermatol. 2021;38(2):371\u20137.","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"848_CR15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s40257-018-00419-1","volume":"20","author":"L Li","year":"2019","unstructured":"Li L, Wei L, Xu ZG, Ma L. No Increased risks associated with propranolol treatment for infantile hemangioma in preterm infants were identified at 3 years of age. Am J Clin Dermatol. 2019;20(2):289\u201393.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"848_CR16","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1159\/000510029","volume":"237","author":"X Wang","year":"2021","unstructured":"Wang X, Feng W, Zhao X, Liu Z, Dong L. The efficacy and safety of topical \u03b2-blockers in treating infantile hemangiomas: a meta-analysis including 11 randomized controlled trials. Dermatology. 2021;237(3):433\u201343.","journal-title":"Dermatology"},{"issue":"1","key":"848_CR17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/lary.26350","volume":"127","author":"RA Bly","year":"2017","unstructured":"Bly RA, Perkins J, Parikh SR. Can topical beta-blockers reduce the size of superficial infantile hemangiomas of the head and neck? Laryngoscope. 2017;127(1):4\u20135.","journal-title":"Laryngoscope"},{"issue":"3","key":"848_CR18","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/bjd.17407","volume":"180","author":"M Novoa","year":"2019","unstructured":"Novoa M, Baselga E, Beltran S, Giraldo L, Shahbaz A, Pardo-Hernandez H, et al. Interventions for infantile haemangiomas of the skin: abridged Cochrane systematic review and GRADE assessments. Br J Dermatol. 2019;180(3):527\u201333.","journal-title":"Br J Dermatol"},{"issue":"10","key":"848_CR19","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s00383-020-04711-2","volume":"36","author":"X Chen","year":"2020","unstructured":"Chen X, Guo Y, Wang P, Qiu F, Sun Y, Shi Q, et al. Efficacy and safety of adrenergic beta-antagonist combined with lasers in the treatment of infantile hemangiomas: a meta-analysis. Pediatr Surg Int. 2020;36(10):1135\u201347.","journal-title":"Pediatr Surg Int"},{"issue":"3","key":"848_CR20","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/1346-8138.14740","volume":"46","author":"J Mashiah","year":"2019","unstructured":"Mashiah J, Hadj-Rabia S, Slodownik D, Harel A, Sprecher E, Kutz A. Effectiveness of topical propranolol 4% gel in the treatment of pyogenic granuloma in children. J Dermatol. 2019;46(3):245\u20138.","journal-title":"J Dermatol"},{"issue":"6","key":"848_CR21","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1111\/jocd.13800","volume":"20","author":"AEAI El-Taweel","year":"2021","unstructured":"El-Taweel AEAI, Al-Refaie AAASA, Salem KHA, Salem RM. Topical \u03b2-blockers for pyogenic granulomas: a promising option for younger patients. J Cosmet Dermatol. 2021;20(6):1801\u20136.","journal-title":"J Cosmet Dermatol."},{"issue":"8","key":"848_CR22","volume":"6","author":"P Sollena","year":"2019","unstructured":"Sollena P, Mannino M, Tassone F, Calegari MA, D\u2019Argento E, Peris K. Efficacy of topical beta-blockers in the management of EGFR-inhibitor induced paronychia and pyogenic granuloma-like lesions: case series and review of the literature. Drugs Context. 2019;6(8): 212613.","journal-title":"Drugs Context"},{"issue":"3","key":"848_CR23","first-page":"22","volume":"13","author":"SM Al Mokadem","year":"2020","unstructured":"Al Mokadem SM, Ibrahim ASM, El Sayed AM. Efficacy of topical timolol 0.5% in the treatment of acne and rosacea: a multicentric study. J Clin Aesthetic Dermatol. 2020;13(3):22\u20137.","journal-title":"J Clin Aesthetic Dermatol."},{"issue":"4","key":"848_CR24","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.jaad.2020.04.129","volume":"83","author":"JGM Logger","year":"2020","unstructured":"Logger JGM, Olydam JI, Driessen RJB. Use of beta-blockers for rosacea-associated facial erythema and flushing: a systematic review and update on proposed mode of action. J Am Acad Dermatol. 2020;83(4):1088\u201397.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"848_CR25","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.2908","volume":"4","author":"V De Giorgi","year":"2018","unstructured":"De Giorgi V, Grazzini M, Benemei S, Marchionni N, Botteri E, Pennacchioli E, et al. Propranolol for off-label treatment of patients with melanoma. JAMA Oncol. 2018;4(2): e172908.","journal-title":"JAMA Oncol"},{"key":"848_CR26","doi-asserted-by":"publisher","unstructured":"The Role of \u03b2-Blockers in Melanoma | SpringerLink [Internet]. [cited 2021 Nov 9]. Available from: https:\/\/link.springer.com\/article\/https:\/\/doi.org\/10.1007\/s11481-019-09876-9","DOI":"10.1007\/s11481-019-09876-9"},{"issue":"11","key":"848_CR27","doi-asserted-by":"publisher","first-page":"E3228","DOI":"10.3390\/cancers12113228","volume":"12","author":"D Katsarelias","year":"2020","unstructured":"Katsarelias D, Eriksson H, Mikiver R, Krakowski I, Nilsson JA, Ny L, et al. The effect of beta-adrenergic blocking agents in cutaneous melanoma-a nation-wide Swedish population-based retrospective register study. Cancers. 2020;12(11):E3228.","journal-title":"Cancers"},{"issue":"6","key":"848_CR28","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1016\/j.jaad.2020.04.144","volume":"84","author":"TP Afra","year":"2021","unstructured":"Afra TP, De D. Topical timolol for postacne erythema. J Am Acad Dermatol. 2021;84(6):e255\u20136.","journal-title":"J Am Acad Dermatol."},{"issue":"5","key":"848_CR29","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/lsm.23354","volume":"53","author":"K Kimwattananukul","year":"2021","unstructured":"Kimwattananukul K, Noppakun N, Asawanonda P, Kumtornrut C. Topical 0.5% timolol maleate significantly enhances skin-barrier restoration after fractional carbon dioxide laser treatment for acne scars. Lasers Surg Med. 2021;53(5):610\u20135.","journal-title":"Lasers Surg Med."},{"issue":"5","key":"848_CR30","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1097\/PRS.0000000000003239","volume":"139","author":"T Enoshiri","year":"2017","unstructured":"Enoshiri T, Naitoh M, Yamawaki S, Kawaguchi A, Aya R, Noda K, et al. \u03b2-adrenergic receptor blockers reduce the occurrence of keloids and hypertrophic scars after cardiac device implantation: a single-institution case\u2013control study. Plast Reconstr Surg. 2017;139(5):1248\u201356.","journal-title":"Plast Reconstr Surg"},{"key":"848_CR31","doi-asserted-by":"crossref","unstructured":"Abdelmaksoud A, Bonamonte D, Giudice G, Filoni A, Vestita M. Topical 1% propranolol in liposomal gel: a new adjuvant tool for chronic leprosy ulcers. Open Dermatol J [Internet]. 2018 May 31 [cited 2021 Nov 9];12(1). Available from: https:\/\/opendermatologyjournal.com\/VOLUME\/12\/PAGE\/59\/FULLTEXT\/","DOI":"10.2174\/1874372201812010059"},{"issue":"1","key":"848_CR32","first-page":"E27","volume":"100","author":"G Dabiri","year":"2017","unstructured":"Dabiri G, Tiger J, Goreshi R, Fischer A, Iwamoto S. Topical timolol may improve overall scar cosmesis in acute surgical wounds. Cutis. 2017;100(1):E27\u20138.","journal-title":"Cutis"},{"issue":"3","key":"848_CR33","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/dth.12328","volume":"29","author":"M Vestita","year":"2016","unstructured":"Vestita M, Bonamonte D, Filoni A. Topical propranolol for a chronic recalcitrant wound: topical propranolol for a chronic recalcitrant wound. Dermatol Ther. 2016;29(3):148\u20139.","journal-title":"Dermatol Ther"},{"issue":"9","key":"848_CR34","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/01.GOX.0000526190.20003.08","volume":"5","author":"M Vestita","year":"2017","unstructured":"Vestita M, Filoni A, Bonamonte D, Annoscia P, Giudice G. Abstract: topical 0.5% timolol for chronic refractory wounds an observational prospective study. Plast Reconstr Surg Glob Open. 2017;5(9):21.","journal-title":"Plast Reconstr Surg Glob Open."},{"issue":"1","key":"848_CR35","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4103\/JCAS.JCAS_13_19","volume":"13","author":"AK Rai","year":"2020","unstructured":"Rai AK, Janani K, Rai R. Efficacy of topical timolol versus saline in chronic venous ulcers: a randomized controlled trial. J Cutan Aesthetic Surg. 2020;13(1):18\u201323.","journal-title":"J Cutan Aesthetic Surg"},{"issue":"3","key":"848_CR36","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1016\/j.jaad.2020.04.070","volume":"84","author":"M Pawar","year":"2021","unstructured":"Pawar M. Topical timolol in chronic, recalcitrant fissures and erosions of hand eczema. J Am Acad Dermatol. 2021;84(3):e125\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"848_CR37","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1016\/j.jaad.2020.05.100","volume":"85","author":"MK Pawar","year":"2021","unstructured":"Pawar MK. Treatment of painful and deep fissures of the heel with topical timolol. J Am Acad Dermatol. 2021;85(1):e3-4.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"848_CR38","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.3892\/mmr.2017.6876","volume":"18","author":"YF Li","year":"2018","unstructured":"Li YF, Chen XY, Lei TC. Inhibitory effect of timolol on topical glucocorticoid-induced skin telangiectasia. Mol Med Rep. 2018;18(3):2823\u201331.","journal-title":"Mol Med Rep"},{"issue":"1","key":"848_CR39","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jaad.2016.08.041","volume":"76","author":"A Abdelmaksoud","year":"2017","unstructured":"Abdelmaksoud A, Filoni A, Giudice G, Vestita M. Classic and HIV-related Kaposi sarcoma treated with 0.1% topical timolol gel. J Am Acad Dermatol. 2017;76(1):153\u20135.","journal-title":"J Am Acad Dermatol."},{"key":"848_CR40","unstructured":"FDA Approves Pierre Fabre\u2019s Hemangeol for Infantile Hemangioma [Internet]. [cited 2021 Nov 10]. Available from: https:\/\/www.fdanews.com\/articles\/163160-fda-approves-pierre-fabres-hemangeol-for-infantile-hemangioma"},{"issue":"4","key":"848_CR41","doi-asserted-by":"publisher","first-page":"e580","DOI":"10.1111\/ajd.13669","volume":"62","author":"M Farshchian","year":"2021","unstructured":"Farshchian M, Potts GA. Transient hypertriglyceridaemia associated with propranolol for treatment of infantile hemangioma. Australas J Dermatol. 2021;62(4):e580\u20131.","journal-title":"Australas J Dermatol"},{"issue":"9","key":"848_CR42","first-page":"984","volume":"18","author":"F Hartmann","year":"2020","unstructured":"Hartmann F, Lockmann A, Himpel O, K\u00fchnle I, Hensen J, Sch\u00f6n MP, et al. Combination therapy of oral propranolol and combined Nd:YAG\/pulsed dye laser therapy in infantile hemangiomas: a retrospective analysis of 48 treated hemangiomas in 30 children. JDDG J Dtsch Dermatol Ges. 2020;18(9):984\u201393.","journal-title":"JDDG J Dtsch Dermatol Ges"},{"issue":"10","key":"848_CR43","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1017\/S1047951118000987","volume":"28","author":"K Chaturvedi","year":"2018","unstructured":"Chaturvedi K, Steinberg JS, Snyder CS. Cost-effectiveness of treating infantile haemangioma with propranolol in an outpatient setting. Cardiol Young. 2018;28(10):1105\u20138.","journal-title":"Cardiol Young"},{"issue":"4","key":"848_CR44","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/pde.13843","volume":"36","author":"E Putterman","year":"2019","unstructured":"Putterman E, Wan J, Streicher JL, Yan AC. Evaluation of a modified outpatient model for using propranolol to treat infantile hemangiomas. Pediatr Dermatol. 2019;36(4):471\u20136.","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"848_CR45","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s12519-018-0137-7","volume":"14","author":"G Frongia","year":"2018","unstructured":"Frongia G, Byeon JO, Arnold R, Mehrabi A, G\u00fcnther P. Cardiac diagnostics before oral propranolol therapy in infantile hemangioma: retrospective evaluation of 234 infants. World J Pediatr WJP. 2018;14(3):254\u20138.","journal-title":"World J Pediatr WJP"},{"issue":"11","key":"848_CR46","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1016\/j.ultrasmedbio.2014.06.021","volume":"40","author":"H Shi","year":"2014","unstructured":"Shi H, Song H, Wang J, Xia L, Yang J, Shang Y, et al. Ultrasound in assessing the efficacy of propranolol therapy for infantile hemangiomas. Ultrasound Med Biol. 2014;40(11):2622\u20139.","journal-title":"Ultrasound Med Biol"},{"issue":"9","key":"848_CR47","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1111\/1346-8138.14517","volume":"45","author":"S Kagami","year":"2018","unstructured":"Kagami S, Kaneko M, Kishi A, Katori T. Prolonged growth of infantile hemangioma after pulsed dye laser and oral propranolol treatment. J Dermatol. 2018;45(9):1109\u201312.","journal-title":"J Dermatol"},{"issue":"4","key":"848_CR48","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15016","volume":"34","author":"A Filoni","year":"2021","unstructured":"Filoni A, Ambrogio F, De Marco A, Pacifico A, Bonamonte D. Topical beta-blockers in dermatologic therapy. Dermatol Ther. 2021;34(4): e15016.","journal-title":"Dermatol Ther"},{"issue":"3","key":"848_CR49","doi-asserted-by":"publisher","first-page":"399","DOI":"10.4103\/ijdvl.IJDVL_220_16","volume":"83","author":"N Prabha","year":"2017","unstructured":"Prabha N, Chhabra N, Arora R. Beta-blockers in dermatology. Indian J Dermatol Venereol Leprol. 2017;83(3):399\u2013407.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"3","key":"848_CR50","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/jdv.14566","volume":"32","author":"L Chen","year":"2018","unstructured":"Chen L, Tsai TF. The role of \u03b2-blockers in dermatological treatment: a review. J Eur Acad Dermatol Venereol JEADV. 2018;32(3):363\u201371.","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"issue":"4","key":"848_CR51","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-0353","volume":"138","author":"C L\u00e9aute-Labr\u00e8ze","year":"2016","unstructured":"L\u00e9aute-Labr\u00e8ze C, Boccara O, Degrugillier-Chopinet C, Mazereeuw-Hautier J, Prey S, Lebb\u00e9 G, et al. Safety of oral propranolol for the treatment of infantile hemangioma: a systematic review. Pediatrics. 2016;138(4): e20160353.","journal-title":"Pediatrics"},{"issue":"10089","key":"848_CR52","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0140-6736(16)00645-0","volume":"390","author":"C L\u00e9aut\u00e9-Labr\u00e8ze","year":"2017","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, Harper JI, Hoeger PH. Infantile haemangioma. Lancet Lond Engl. 2017;390(10089):85\u201394.","journal-title":"Lancet Lond Engl"},{"issue":"3","key":"848_CR53","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/bjd.17574","volume":"180","author":"JE Mellerio","year":"2019","unstructured":"Mellerio JE. Beta blockers for infantile haemangiomas: where should we go from here? Br J Dermatol. 2019;180(3):450\u20131.","journal-title":"Br J Dermatol"},{"issue":"5","key":"848_CR54","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/ICU.0000000000000591","volume":"30","author":"C Al-Haddad","year":"2019","unstructured":"Al-Haddad C, El Salloukh NA, El Moussawi Z. \u03b2-blockers in the treatment of periocular infantile hemangioma. Curr Opin Ophthalmol. 2019;30(5):319\u201325.","journal-title":"Curr Opin Ophthalmol"},{"issue":"4","key":"848_CR55","first-page":"E17","volume":"99","author":"KE Oberlin","year":"2017","unstructured":"Oberlin KE. Expanding uses of propranolol in dermatology. Cutis. 2017;99(4):E17\u20139.","journal-title":"Cutis"},{"issue":"6","key":"848_CR56","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/jamadermatol.2017.0250","volume":"153","author":"KH Kim","year":"2017","unstructured":"Kim KH, Choi TH, Choi Y, Park YW, Hong KY, Kim DY, et al. Comparison of efficacy and safety between propranolol and steroid for infantile hemangioma: a randomized clinical trial. JAMA Dermatol. 2017;153(6):529\u201336.","journal-title":"JAMA Dermatol"},{"issue":"10","key":"848_CR57","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1111\/1346-8138.13324","volume":"43","author":"L Hu","year":"2016","unstructured":"Hu L, Zhou B, Huang H, Chang L, Qiu Y, Ma G, et al. Effects of systemic propranolol treatment on physical growth of patients with infantile hemangiomas. J Dermatol. 2016;43(10):1160\u20136.","journal-title":"J Dermatol"},{"issue":"3","key":"848_CR58","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jaad.2015.09.061","volume":"74","author":"H Zaher","year":"2016","unstructured":"Zaher H, Rasheed H, El-Komy MM, Hegazy RA, Gawdat HI, Abdel Halim DM, et al. Propranolol versus captopril in the treatment of infantile hemangioma (IH): a randomized controlled trial. J Am Acad Dermatol. 2016;74(3):499\u2013505.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"848_CR59","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2017-3866","volume":"142","author":"E Baselga","year":"2018","unstructured":"Baselga E, Dembowska-Baginska B, Przewratil P, Gonz\u00e1lez-Ense\u00f1at MA, Wyrzykowski D, Torrelo A, et al. Efficacy of propranolol between 6 and 12 months of age in high-risk infantile hemangioma. Pediatrics. 2018;142(3): e20173866.","journal-title":"Pediatrics"},{"issue":"6","key":"848_CR60","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/1346-8138.14316","volume":"45","author":"S Kagami","year":"2018","unstructured":"Kagami S, Kaneko M, Katori T. Thirty-two Japanese cases of infantile hemangiomas treated with oral propranolol. J Dermatol. 2018;45(6):719\u201322.","journal-title":"J Dermatol"},{"issue":"8","key":"848_CR61","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/ped.13318","volume":"59","author":"T Kaneko","year":"2017","unstructured":"Kaneko T, Sasaki S, Baba N, Koh K, Matsui K, Ohjimi H, et al. Efficacy and safety of oral propranolol for infantile hemangioma in Japan. Pediatr Int Off J Jpn Pediatr Soc. 2017;59(8):869\u201377.","journal-title":"Pediatr Int Off J Jpn Pediatr Soc"},{"key":"848_CR62","unstructured":"Comparing the Clinical, Radiologic and Biochemical Effectiveness of Atenolol and Propranolol in the Treatment of Infantile Hemangioma - A Randomized Controlled Trial by Raihan Ashraf, Rahul Mahajan, Muneer Abas, Sanjeev Handa, Anindita Sinha, Dipankar De, Naresh Sachdev:: SSRN [Internet]. [cited 2022 May 30]. Available from: https:\/\/papers.ssrn.com\/sol3\/papers.cfm?abstract_id=3353380"},{"issue":"8","key":"848_CR63","first-page":"449","volume":"25","author":"A Lahrichi","year":"2018","unstructured":"Lahrichi A, Hali F, Baline K, Fatoiki FZE, Chiheb S, Khadir K. Effects of propranolol therapy in Moroccan children with infantile hemangioma. Arch Pediatr Organe Off Soc Francaise Pediatr. 2018;25(8):449\u201351.","journal-title":"Arch Pediatr Organe Off Soc Francaise Pediatr"},{"issue":"3","key":"848_CR64","doi-asserted-by":"publisher","first-page":"139","DOI":"10.11622\/smedj.2020008","volume":"62","author":"JMC Tan","year":"2021","unstructured":"Tan JMC, Lim HW, Koh MJA. Oral propranolol for the treatment of infantile haemangiomas in Singapore. Singapore Med J. 2021;62(3):139\u201342.","journal-title":"Singapore Med J"},{"key":"848_CR65","doi-asserted-by":"publisher","unstructured":"Treatment with propranolol for infantile hemangiomas: single\u2010center experience\u2014Turhan. J Cosmet Dermatol Wiley Online Library 2016 [Internet]. [cited 2021 Nov 10]. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/https:\/\/doi.org\/10.1111\/jocd.12220","DOI":"10.1111\/jocd.12220"},{"issue":"6","key":"848_CR66","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14283","volume":"33","author":"L Tognetti","year":"2020","unstructured":"Tognetti L, Pianigiani E, Ierardi F, Cartocci A, Fiorani D, de Quattro M, et al. A new clinical and dermoscopic monitoring of infantile hemangiomas treated with oral propranolol. Dermatol Ther. 2020;33(6): e14283.","journal-title":"Dermatol Ther"},{"issue":"11","key":"848_CR67","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/lary.26818","volume":"127","author":"T Schwartz","year":"2017","unstructured":"Schwartz T, Faria J, Pawar S, Siegel D, Chun RH. Efficacy and rebound rates in propranolol-treated subglottic hemangioma: a literature review. Laryngoscope. 2017;127(11):2665\u201372.","journal-title":"Laryngoscope"},{"issue":"3","key":"848_CR68","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/pde.13816","volume":"36","author":"DB Mannschreck","year":"2019","unstructured":"Mannschreck DB, Huang AH, Lie E, Psoter K, Puttgen K. Topical timolol as adjunct therapy to shorten oral propranolol therapy for infantile hemangiomas. Pediatr Dermatol. 2019;36(3):283\u20139.","journal-title":"Pediatr Dermatol"},{"key":"848_CR69","unstructured":"Oral propranolol combined with topical timolol for compound infantile hemangiomas: a retrospective study | Scientific Reports [Internet]. [cited 2022 May 30]. Available from: https:\/\/www.nature.com\/articles\/srep19765#Tab2"},{"issue":"7","key":"848_CR70","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/1346-8138.13763","volume":"44","author":"X Yu","year":"2017","unstructured":"Yu X, Zhang J, Wu Z, Liu M, Chen R, Gu Y, et al. LUMBAR syndrome: A case manifesting as cutaneous infantile hemangiomas of the lower extremity, perineum and gluteal region, and a review of published work. J Dermatol. 2017;44(7):808\u201312.","journal-title":"J Dermatol"},{"issue":"6","key":"848_CR71","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14520","volume":"33","author":"BH Seo","year":"2020","unstructured":"Seo BH, Kim DH, Suh HS, Choi YS. Facial flushing and erythema of rosacea improved by carvedilol. Dermatol Ther. 2020;33(6): e14520.","journal-title":"Dermatol Ther"},{"issue":"3","key":"848_CR72","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/CMR.0000000000000317","volume":"27","author":"V De Giorgi","year":"2017","unstructured":"De Giorgi V, Grazzini M, Benemei S, Marchionni N, Geppetti P, Gandini S. \u03b2-Blocker use and reduced disease progression in patients with thick melanoma: 8 years of follow-up. Melanoma Res. 2017;27(3):268\u201370.","journal-title":"Melanoma Res"},{"key":"848_CR73","unstructured":"Oxford Centre for Evidence-Based Medicine: Levels of Evidence (March 2009) \u2014 Centre for Evidence-Based Medicine (CEBM), University of Oxford [Internet]. [cited 2022 May 30]. Available from: https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009"},{"issue":"10","key":"848_CR74","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.2340\/00015555-2681","volume":"97","author":"M Khan","year":"2017","unstructured":"Khan M, Boyce A, Prieto-Merino D, Svensson \u00c5, Wedgeworth E, Flohr C. The role of topical timolol in the treatment of infantile hemangiomas: a systematic review and meta-analysis. Acta Derm Venereol. 2017;97(10):1167\u201371.","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"848_CR75","doi-asserted-by":"publisher","first-page":"e303","DOI":"10.1111\/jdv.17057","volume":"35","author":"QY Chen","year":"2021","unstructured":"Chen QY, Chang L, Qiu YJ, Ying HR, Chang SJ, Zhang Y, et al. Comparison of the efficacy between topical timolol and pulsed dye laser in the treatment of ulcerated infantile haemangiomas: a randomized controlled study. J Eur Acad Dermatol Venereol JEADV. 2021;35(4):e303\u20135.","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"issue":"6","key":"848_CR76","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/1346-8138.13747","volume":"44","author":"H Ying","year":"2017","unstructured":"Ying H, Zou Y, Yu W, Qiu Y, Ma G, Chang L, et al. Prospective, open-label, rater-blinded and self-controlled pilot study of the treatment of proliferating superficial infantile hemangiomas with 0.5% topical timolol cream versus 595-nm pulsed dye laser. J Dermatol. 2017;44(6):660\u20135.","journal-title":"J Dermatol"},{"issue":"1","key":"848_CR77","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/pde.13361","volume":"35","author":"LQ Gan","year":"2018","unstructured":"Gan LQ, Wang H, Ni SL, Tan CH. A prospective study of topical carteolol therapy in Chinese infants with superficial infantile hemangioma. Pediatr Dermatol. 2018;35(1):121\u20135.","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"848_CR78","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/ijd.13517","volume":"56","author":"J Mashiah","year":"2017","unstructured":"Mashiah J, Kutz A, Rabia SH, Ilan EB, Goldberg I, Sprecher E, et al. Assessment of the effectiveness of topical propranolol 4% gel for infantile hemangiomas. Int J Dermatol. 2017;56(2):148\u201353.","journal-title":"Int J Dermatol"},{"issue":"1","key":"848_CR79","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/pde.13372","volume":"35","author":"I Neri","year":"2018","unstructured":"Neri I, Baraldi C, Balestri R, Piraccini BM, Patrizi A. Topical 1% propranolol ointment with occlusion in treatment of pyogenic granulomas: an open-label study in 22 children. Pediatr Dermatol. 2018;35(1):117\u201320.","journal-title":"Pediatr Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-022-00848-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-022-00848-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-022-00848-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T10:33:52Z","timestamp":1728470032000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-022-00848-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,22]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["848"],"URL":"https:\/\/doi.org\/10.1007\/s13555-022-00848-1","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,22]]},"assertion":[{"value":"28 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}